Pipeline-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta has established a pipeline of 15 innovative molecules in oncology, bone disorders and nephrology. 14 of them are discovered and developed in house.

Oncology pipeline includes multiple innovative and differentiated biologic molecules targeting major cancer pathways which have potential synergistic mechanisms of actions for tumor indications with high unmet medical needs. Our pipeline includes both targeted therapy Osemitamab (TST001) as well as immunotherapy (TST005) that engage either NK cells or T cells to kill tumor cells, or agents that can enhance the anti-tumor activity of the above mentioned therapies by either inhibiting tumor associated fibroblast derived immunosuppressive regulatory protein (TST003) or depleting immunosuppressive Treg cells (TST010) or by enhancing TIL infiltration into the tumor by normalizing vasculature (MSB0254).

Transcenta’s highly differentiated non-oncology pipelines focus on novel indications with high unmet medical needs in bone and kidney diseases. TST002 and TST004 are two differentiated molecules that are designed to treat osteoporosis and complement mediated disease respectively. Both osteoporosis and kidney disease like IgAN are areas of high unmet medical needs and with high market potentials.

Oncology

Drugs
Candidate

Target

Indication

Modality

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Rights

Partner

Osemitamab (TST001)

Claudin 18.2

G/GEJC 1L

PADC 1L

mAb

Osemitamab (TST001)

More + More +

Drugs Candidate:Claudin 18.2

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

G/GEJC 1L -mAb - Combo with PL1/Chemo

Combo with PL1/Chemo

G/GEJC 1L - - Combo with Chemo

Combo with Chemo

PADC 1L - - Combo with Chemo

Combo with Chemo

Global

In-house

READ MORE READ MORE

TST003

Gremlin-1 (FIC)

Solid Tumors

mAb

TST003

More + More +

Drugs Candidate:Gremlin-1 (FIC)

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -mAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST006

Claudin 18.2/PDL1

Solid Tumors

BsAb

TST006

More + More +

Drugs Candidate:Claudin 18.2/PDL1

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -BsAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST010

Undisclosed

Solid Tumors

mAb

TST010

More + More +

Drugs Candidate:Undisclosed

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -mAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST105

FGFR2b Bi-Specific

Solid tumors

ADC

TST105

More + More +

Drugs Candidate:FGFR2b Bi-Specific

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid tumors -ADC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST012

FGFR2b

Solid Tumors

ADC

TST012

More + More +

Drugs Candidate:FGFR2b

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -ADC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST013

LIV-1

Solid Tumors

ADC

TST013

More + More +

Drugs Candidate:LIV-1

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -ADC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

MSB2311

PD-L1

Solid Tumors

mAb

MSB2311

More + More +

Drugs Candidate:PD-L1

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -mAb - Monotherapy/Combo with VEGFRi

Monotherapy/Combo with VEGFRi

Global

In-house

READ MORE READ MORE

MSB0254

VEGFR2

Solid Tumors

mAb

MSB0254

More + More +

Drugs Candidate:VEGFR2

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -mAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST005

PD-L1/TGF-β

Solid Tumors

BsP

TST005

More + More +

Drugs Candidate:PD-L1/TGF-β

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -BsP - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

Non-oncology

Drugs
Candidate

Target

Indication

Modality

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Rights

Partner

Blosozumab (TST002)

Sclerostin

Osteoporosis

mAb

Blosozumab (TST002)

More + More +

Drugs Candidate:Sclerostin

Right:Greater China

Partner:In-licensed from Eli Lilly

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Osteoporosis -mAb - Monotherapy

Monotherapy

Greater China

In-licensed from Eli Lilly

READ MORE READ MORE

TST004

MASP2

IgAN, TMA

mAb

TST004

More + More +

Drugs Candidate:MASP2

Right:Global

Partner:Co-development with Alebund in Greater China

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

IgAN, TMA -mAb - Monotherapy

Monotherapy

Global

Co-development with Alebund in Greater China

READ MORE READ MORE

TST008

MSAP2/BAFF (FIC)

SLE/LN/IgAN

BsAb

TST008

More + More +

Drugs Candidate:MSAP2/BAFF (FIC)

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

SLE/LN/IgAN -BsAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST801

BAFF/APRIL (FIC)

SLE/LN/IgAN

BsP

TST801

More + More +

Drugs Candidate:BAFF/APRIL (FIC)

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

SLE/LN/IgAN -BsP - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST808

Undisclosed

IgAN

mAb

TST808

More + More +

Drugs Candidate:Undisclosed

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

IgAN -mAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE